Reaction Details Report a problem with these data
Target
Early activation antigen CD69
Ligand
BDBM50161162
Substrate
n/a
Meas. Tech.
ChEMBL_2158455 (CHEMBL5043205)
IC50
3100±n/a nM
Citation
 Hopkins, BT; Bame, E; Bajrami, B; Black, C; Bohnert, T; Boiselle, C; Burdette, D; Burns, JC; Delva, L; Donaldson, D; Grater, R; Gu, C; Hoemberger, M; Johnson, J; Kapadnis, S; King, K; Lulla, M; Ma, B; Marx, I; Magee, T; Meissner, R; Metrick, CM; Mingueneau, M; Murugan, P; Otipoby, KL; Polack, E; Poreci, U; Prince, R; Roach, AM; Rowbottom, C; Santoro, JC; Schroeder, P; Tang, H; Tien, E; Zhang, F; Lyssikatos, J Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. J Med Chem 65:1206-1224 (2022) [PubMed]  Article 
Target
Name:
Early activation antigen CD69
Synonyms:
AIM | Activation inducer molecule | BL-AC/P26 | C-type lectin domain family 2 member C | CD69 | CD69_HUMAN | CD_antigen=CD69 | CLEC2C | EA1 | Early T-cell activation antigen p60 | Early activation antigen CD69 | GP32/28 | Leukocyte surface antigen Leu-23 | MLR-3
Type:
PROTEIN
Mol. Mass.:
22559.65
Organism:
Homo sapiens
Description:
ChEMBL_109097
Residue:
199
Sequence:
MSSENCFVAENSSLHPESGQENDATSPHFSTRHEGSFQVPVLCAVMNVVFITILIIALIALSVGQYNCPGQYTFSMPSDSHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATLAVIDSEKDMNFLKRYAGREEHWVGLKKEPGHPWKWSNGKEFNNWFNVTGSDKCVFLKNTEVSSMECEKNLYWICNKPYK
  
Inhibitor
Name:
BDBM50161162
Synonyms:
AVL-292 | CC-292 | Spebrutinib | US10596172, Compound I-182 | US10828300, Compound I-182 | US11351168, Compound I-182 | US9987276, Compound I-182
Type:
Small organic molecule
Emp. Form.:
C22H22FN5O3
Mol. Mass.:
423.4402
SMILES:
COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1
Structure:
Search PDB for entries with ligand similarity: